Ivan Spicka

5PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|Dec 27, 2025
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Gurdeep Parmar, Marcelo Capra, Fernanda Seguro

|Nov 28, 2024
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.

Paul G Richardson, Aurore Perrot, Joseph Mikhael

|Jul 18, 2024
A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

Meletios A Dimopoulos, Daniel Coriu, Sosana Delimpasi

|Sep 26, 2023
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.

Viera Sandecka, Tereza Popkova, Martin Stork

Pageof 1

Frequent Collaborators

2 joint publications

Tomas Jelinek

2 joint publications

Meral Beksac

2 joint publications

Roman Hájek

2 joint publications

Jiří Minařík